Development of cancer antigen-specific T cell therapy including utilization of iPS cells

As described in the section on development of cancer vaccine therapy, we identified HLA-restricted peptides that can induce peptide-specific CTLs derived from the original cancer antigens glypican-3 (GPC3) and HSP105, and have conducted clinical trials of cancer peptide vaccine therapy. We could establish many and many kinds of peptide-specific CTL clones from peripheral blood and tumor tissues of the administered patient. We are developing a T cell therapy derived from iPS cells transfected with these TCRs in collaboration with companies / academia. In addition, GPC3 is also a membrane protein, and we are also working on the development of CAR gene-introduced T cell therapy targeting GPC3, together with companies and academia.